TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 9142-9156

  Qiu, Bo ^a   Sun, Xiyang ^b   Zhang, Dongyong ^a   Wang, Yong ^a   Tao, Jun ^a   Ou, Shaowu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; Glioma stem cells; Paclitaxel; Tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL); U87 derived stem like cells (U87 SLCs)

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN CLEAVAGE; UPREGULATION; AGONISTS; BIOSYNTHESIS; CANCER STEM CELL; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLIOMA; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PACLITAXEL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84864326663     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13079142     Document Type: Article

References (49)

1. Bondy, M.L.; Scheurer, M.E.; Malmer, B.; Barnholtz-Sloan, J.S.; Davis, F.G.; Il'yasova, D.; Kruchko, C.; McCarthy, B.J.; Rajaraman, P.; Schwartzbaum, J.A.; et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113, 1953-1968.
2. Hess, K.R.; Broglio, K.R.; Bondy, M.L. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004, 101, 2293-2299.
3. Park, D.M.; Rich, J.N. Biology of glioma cancer stem cells. Mol. Cells 2009, 28, 7-12.
4. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
5. Stummer, W.; Kamp, M.A. The importance of surgical resection in malignant glioma. Curr. Opin. Neurol. 2009, 22, 645-649.
6. Stummer, W.; van den Bent, M.J.; Westphal, M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: New arguments in an old discussion. Acta. Neurochir. (Wien) 2011, 153, 1211-1218.
7. Holdhoff, M.; Grossman, S.A. Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 2011, 16, 351-358.
8. Stupp, R.; Hegi, M.E.; Gilbert, M.R.; Chakravarti, A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J. Clin. Oncol. 2007, 25, 4127-4136.
9. Duesberg, P.; Li, R.; Sachs, R.; Fabarius, A.; Upender, M.B.; Hehlmann, R. Cancer drug resistance: The central role of the karyotype. Drug Resist. Updates 2007, 10, 51-58.
10. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284.
11. Frosina, G. Frontiers in targeting glioma stem cells. Eur. J. Cancer 2011, 47, 496-507.
12. Lamszus, K.; Gunther, H.S. Glioma stem cells as a target for treatment. Target Oncol. 2010, 5, 211-215.
13. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67.
14. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; de Vitis, S.; Fiocco, R.; Foroni, C.; Dimeco, F.; Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64, 7011-7021.
15. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
16. Yuan, X.; Curtin, J.; Xiong, Y.; Liu, G.; Waschsmann-Hogiu, S.; Farkas, D.L.; Black, K.L.; Yu, J.S. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23, 9392-9400.
17. Dalerba, P.; Cho, R.W.; Clarke, M.F. Cancer stem cells: Models and concepts. Annu. Rev. Med. 2007, 58, 267-284.
18. Eyler, C.E.; Rich, J.N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26, 2839-2845.
19. Hide, T.; Takezaki, T.; Nakamura, H.; Kuratsu, J.; Kondo, T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. 2008, 25, 67-72.
20. Venere, M.; Fine, H.A.; Dirks, P.B.; Rich, J.N. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia 2011, 59, 1148-1154.
21. Suliman, A.; Lam, A.; Datta, R.; Srivastava, R.K. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001, 20, 2122-2133.
22. Smyth, M.J.; Takeda, K.; Hayakawa, Y.; Peschon, J.J.; van den Brink, M.R.; Yagita, H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003, 18, 1-6.
23. Kuijlen, J.M.; Bremer, E.; Mooij, J.J.; den Dunnen, W.F.; Helfrich, W. Review: On TRAIL for malignant glioma therapy? Neuropathol. Appl. Neurobiol. 2010, 36, 168-182.
24. Mora, R.; Abschuetz, A.; Kees, T.; Dokic, I.; Joschko, N.; Kleber, S.; Geibig, R.; Mosconi, E.; Zentgraf, H.; Martin-Villalba, A.; et al. TNF-α- and TRAIL-resistant glioma cells undergo autophagy-dependent cell death induced by activated microglia. Glia 2009, 57, 561-581.
25. Shankar, S.; Srivastava, R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications. Drug Resist. Updates 2004, 7, 139-156.
26. Zhang, L.; Fang, B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12, 228-237.
27. Baritaki, S.; Huerta-Yepez, S.; Sakai, T.; Spandidos, D.A.; Bonavida, B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer Ther. 2007, 6, 1387-1399.
28. Kim, M.; Liao, J.; Dowling, M.L.; Voong, K.R.; Parker, S.E.; Wang, S.; El-Deiry, W.S.; Kao, G.D. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res. 2008, 68, 3440-3449.
29. Chang, S.M.; Kuhn, J.G.; Robins, H.I.; Schold, S.C., Jr.; Spence, A.M.; Berger, M.S.; Mehta, M.; Pollack, I.F.; Rankin, C.; Prados, M.D. A study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: A North American Brain Tumor Consortium report. Cancer 2001, 91, 417-422.
30. Postma, T.J.; Heimans, J.J.; Luykx, S.A.; van Groeningen, C.J.; Beenen, L.F.; Hoekstra, O.S.; Taphoorn, M.J.; Zonnenberg, B.A.; Klein, M.; Vermorken, J.B. A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann. Oncol. 2000, 11, 409-413.
31. Dorsey, J.F.; Mintz, A.; Tian, X.; Dowling, M.L.; Plastaras, J.P.; Dicker, D.T.; Kao, G.D.; El-Deiry, W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther. 2009, 8, 3285-3295.
32. Sun, X.; Pang, Z.; Ye, H.; Qiu, B.; Guo, L.; Li, J.; Ren, J.; Qian, Y.; Zhang, Q.; Chen, J.; et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 2012, 33, 916-924.
33. Yu, C.C.; Chiou, G.Y.; Lee, Y.Y.; Chang, Y.L.; Huang, P.I.; Cheng, Y.W.; Tai, L.K.; Ku, H.H.; Chiou, S.H.; Wong, T.T. Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity. Childs Nerv. Syst. 2010, 26, 897-904.
34. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253-1261.
35. Wang, J.; Wang, X.; Jiang, S.; Lin, P.; Zhang, J.; Wu, Y.; Xiong, Z.; Ren, J.J.; Yang, H. Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme. Cell Mol. Neurobiol. 2008, 28, 991-1003.
36. Capper, D.; Gaiser, T.; Hartmann, C.; Habel, A.; Mueller, W.; Herold-Mende, C.; von Deimling, A.; Siegelin, M.D. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009, 117, 445-456.
37. Lu, C.; Shervington, A. Chemoresistance in gliomas. Mol. Cell Biochem. 2008, 312, 71-80.
38. Cai, S.; Xu, Y.; Cooper, R.J.; Ferkowicz, M.J.; Hartwell, J.R.; Pollok, K.E.; Kelley, M.R. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Res. 2005, 65, 3319-3327.
39. Hirschmann-Jax, C.; Foster, A.E.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 14228-14233.
40. Mellor, H.R.; Ferguson, D.J.; Callaghan, R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br. J. Cancer 2005, 93, 302-309.
41. Asakuma, J.; Sumitomo, M.; Asano, T.; Hayakawa, M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res. 2003, 63, 1365-1370.
42. Hunter, T.B.; Manimala, N.J.; Luddy, K.A.; Catlin, T.; Antonia, S.J. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res. 2011, 31, 3193-3204.
43. Park, S.J.; Wu, C.H.; Gordon, J.D.; Zhong, X.; Emami, A.; Safa, A.R. Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem. 2004, 279, 51057-51067.
44. Singh, T.R.; Shankar, S.; Chen, X.; Asim, M.; Srivastava, R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003, 63, 5390-5400.
45. Saqr, H.E.; Omran, O.M.; Oblinger, J.L.; Yates, A.J. TRAIL-induced apoptosis in U-1242 MG glioma cells. J. Neuropathol. Exp. Neurol. 2006, 65, 152-161.
46. Walczak, H.; Bouchon, A.; Stahl, H.; Krammer, P.H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL- overexpressing chemotherapy-resistant tumor cells. Cancer Res. 2000, 60, 3051-3057.
47. Qiu, B.; Zhang, D.; Tao, J.; Tie, X.; Wu, A.; Wang, Y. Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro. J. Clin. Neurosci. 2012, 19, 130-134.
48. Cao, S.S.; Zhen, Y.S. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother. Pharmacol. 1989, 24, 181-186.
49. Kogel, D.; Schomburg, R.; Copanaki, E.; Prehn, J.H. Regulation of gene expression by the amyloid precursor protein: Inhibition of the JNK/c-Jun pathway. Cell Death Differ. 2005, 12, 1-9.